John E. Nosenzo's most recent trade in TELA Bio Inc was a trade of 5,360 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 1, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TELA Bio Inc | John E. Nosenzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,360 | 5,360 | - | - | Stock Option (Right to Buy) | |
| TELA Bio Inc | John E. Nosenzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 3,135 | 6,270 (0%) | 0% | 0 | Common Stock | |
| TELA Bio Inc | John E. Nosenzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 5,360 | 5,360 | - | - | Stock Option (Right to Buy) | |
| TELA Bio Inc | John E. Nosenzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 3,135 | 3,135 (0%) | 0% | 0 | Common Stock | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 106,485 | 0 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 106,485 | 149,895 (0%) | 0% | - | Class A Common Stock | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 11.12 per share. | 01 Apr 2022 | 65,963 | 83,932 (0%) | 0% | 11.1 | 733,502 | Class A Common Stock |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Fmr. Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 01 Apr 2022 | 95 | 87,155 (0%) | 0% | 6.7 | 639 | Class A Common Stock |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Fmr. Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.08 per share. | 01 Apr 2022 | 40 | 87,250 (0%) | 0% | 14.1 | 563 | Class A Common Stock |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Fmr. Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 01 Apr 2022 | 7 | 87,148 (0%) | 0% | 7 | 49 | Class A Common Stock |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 1,470 | 43,904 (0%) | 0% | - | Class A Common Stock | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 1,470 | 0 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 11.99 per share. | 11 Feb 2022 | 534 | 43,370 (0%) | 0% | 12.0 | 6,401 | Class A Common Stock |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 66,139 | 66,639 (0%) | 0% | - | Class A Common Stock | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 66,139 | 0 | - | - | Phantom Profit Units | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.88 per share. | 10 Feb 2022 | 24,205 | 42,434 (0%) | 0% | 12.9 | 311,760 | Class A Common Stock |
| TELA Bio Inc | John E. Nosenzo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 8,000 | 8,000 | - | - | Stock Option (Right to Buy) | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 106,485 | 106,485 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 1,470 | 1,470 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | John E. Nosenzo | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 11 Feb 2021 | 500 | 500 (0%) | 0% | 13 | 6,500 | Common Stock |